The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program.
Health Aff (Millwood)
; 42(5): 632-641, 2023 05.
Article
em En
| MEDLINE
| ID: mdl-37126754
ABSTRACT
Biosimilar drugs-lower-cost alternatives to expensive biologic drugs-have the potential to slow the growth of US drug spending. However, rates of biosimilar uptake have varied across hospital outpatient providers. We investigated whether the 340B Drug Pricing Program, which offers eligible hospitals substantial discounts on drug purchases, inhibits biosimilar uptake. Almost one-third of US hospitals participate in the 340B program. Using a regression discontinuity design and two high-volume biologics with biosimilar competitors, filgrastim and infliximab, we estimated that 340B program eligibility was associated with a 22.9-percentage-point reduction in biosimilar adoption. In addition, 340B program eligibility was associated with 13.3 more biologic administrations annually per hospital and $17,919 more biologic revenue per hospital. Our findings suggest that the program inhibited biosimilar uptake, possibly as a result of financial incentives making reference drugs more profitable than biosimilar medications.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Reembolso de Incentivo
/
Medicare
/
Medicamentos Biossimilares
Tipo de estudo:
Evaluation_studies
/
Health_economic_evaluation
Limite:
Aged
/
Humans
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article